Drug intelligence / Profile preview

AME-1

Development stage: Preclinical
Lead developer: Psyched Wellness
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

AME-1 is a proprietary **Amanita muscaria** mushroom extract being developed by Psyched Wellness as a mushroom-derived oral wellness product. Based on the provided materials, it is a natural water-based extract intended primarily for stress relief, relaxation, and support of restful sleep, with additional preclinical findings suggesting inhibition of human mast cell activation and a potential immune-priming effect. It is not a synthetic small molecule or biologic, and its precise molecular pharmacology and primary validated therapeutic target have not been clearly established in the supplied sources.

Other names: Amanita muscaria extract

Beyond the preview

Go deeper on AME-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AME-1.

Explore the full profile